Abbott Laboratories has received U.S. Food and Drug Administration authorization for Libre Duo 10 Day, a wearable sensor that measures glucose and ketone levels continuously through the same device and transmits readings to a compatible smartphone every minute. Authorized for people aged two years and older with diabetes, Libre Duo becomes the first U.S. wearable capable of continuous ketone monitoring and the first device globally authorized to continuously track both glucose and ketones together. Abbott Laboratories plans to launch the system in the United States later in 2026.
The development addresses a blind spot in conventional continuous glucose monitoring. Glucose sensors can reveal whether blood sugar is rising, falling or remaining stable, but diabetic ketoacidosis can involve another biochemical warning signal: increasing ketone levels as the body begins relying heavily on fat for energy. Until now, patients who suspected rising ketones generally had to perform a separate urine or blood test that produced a single snapshot rather than a continuous trend.
Why does continuously monitoring ketones matter for diabetes care?
Diabetic ketoacidosis, commonly known as DKA, can develop when insufficient insulin prevents cells from using glucose effectively, causing the body to break down fat and generate ketones. Excessive ketone accumulation can make the blood dangerously acidic, and the condition can progress into a medical emergency requiring hospital treatment.
The risk is particularly relevant for people with type 1 diabetes, although DKA can also occur in other circumstances. The FDA cited an estimated 2.1 million Americans living with type 1 diabetes and emphasized that recognizing an upward ketone trend before symptoms become severe could create a window for earlier intervention.
Conventional ketone tests answer a relatively narrow question: what is the ketone concentration at this moment? Continuous sensing adds direction and velocity. A patient can potentially see whether concentrations are stable, gradually climbing or accelerating toward a concerning range, making the information more analogous to the trend arrows that changed how people use continuous glucose data.
How does Abbott Libre Duo monitor glucose and ketones?
Libre Duo 10 Day measures glucose and ketone concentrations in interstitial fluid beneath the skin throughout a ten-day wear period. Measurements are transmitted every minute to a compatible smartphone, allowing users to view both current levels and directional trends without performing a separate ketone test each time.
The system can automatically alert users when ketone concentrations reach a concerning threshold. Importantly, the FDA cautions that ketone information should be interpreted alongside glucose readings, symptoms and the broader clinical situation rather than treated as an isolated diagnostic signal.
That integration may prove to be one of the device’s most consequential features. Instead of asking patients to remember when a second test is necessary, ketone surveillance can operate continuously in the background while the user manages glucose through the interface already associated with modern diabetes sensing.
What evidence supported the FDA authorization?
The FDA reviewed clinical and performance evidence from six studies involving more than 600 participants aged two years and older. Those studies evaluated both glucose and ketone accuracy across different concentration ranges and throughout the device’s ten-day wear period.
According to the agency, Libre Duo accurately captured clinically meaningful differences in ketone levels and was able to identify elevated concentrations before diabetic ketoacidosis developed. That evidence was particularly important because continuous ketone sensing represents a new device category rather than a simple incremental modification to an established glucose monitor.
The FDA used the De Novo pathway, which establishes a new regulatory classification for novel low- to moderate-risk devices without a legally marketed predicate. Libre Duo had previously received Breakthrough Device designation, and the authorization establishes special controls governing areas including labeling and performance testing.
Abbott Laboratories said the authorization establishes both an integrated continuous glucose monitoring standard and a new integrated continuous glucose-and-ketone monitoring standard, potentially creating a regulatory pathway that competing manufacturers can subsequently follow.
Could dual-analyte sensors become the next stage of continuous monitoring?
The significance of Libre Duo extends beyond ketones because it demonstrates that continuous biosensors are beginning to move from single-analyte devices toward multi-analyte platforms. Continuous glucose monitoring has already established the commercial and clinical infrastructure for wearable biochemical sensing, including smartphone connectivity, alerts and remote data sharing.
Adding another biomarker changes the underlying proposition. Rather than building a separate wearable for every biological measurement, manufacturers may increasingly attempt to combine multiple sensing chemistries within one patch and one digital interface.
That transition will not be simple. Different biomarkers exist at different concentrations, behave differently in interstitial fluid and require distinct calibration, stability and interference controls. Regulatory validation also becomes more complicated because every additional analyte creates another stream of information capable of influencing medical decisions.
Libre Duo nevertheless provides evidence that the multi-analyte model can reach regulatory authorization. In diabetes, the immediate benefit is linking daily glucose control with an early warning biomarker for a dangerous acute complication.
What could Libre Duo change for patients and diabetes-device companies?
For patients, the largest potential benefit is reducing the cognitive burden surrounding ketone testing. A person already dealing with insulin dosing, food, exercise, illness and glucose fluctuations no longer has to initiate every ketone check manually if the sensor is continuously measuring the biomarker in the background.
For Abbott Laboratories, the product expands the Libre franchise from continuous glucose monitoring into continuous metabolic monitoring. The distinction could become strategically important as competition in conventional continuous glucose monitoring intensifies and manufacturers search for additional biomarkers, algorithms and clinical functions capable of differentiating their platforms.
The unanswered question is how often continuous ketone information will meaningfully alter everyday treatment outside high-risk periods such as illness, insulin interruption or rapidly deteriorating glucose control. Real-world adoption will therefore depend not merely on sensor accuracy but on whether alerts produce earlier intervention without generating unnecessary anxiety or excessive clinical escalation.
The broader direction, however, is becoming clearer. Continuous monitoring is moving beyond telling patients what one biomarker is doing and toward creating a richer physiological picture from a single wearable. Libre Duo makes ketones the next analyte to cross that threshold.
